Anti-HIV activity of MDL 74968, a novel acyclonucleotide derivative of guanine: Drug resistance and drug combination effects in vitro

Antiviral Chemistry and Chemotherapy

Volumn 7, Issue 5, 1996, Pages 253-260

  Taylor, D L ^a   Ahmed, S P ^a   Brennan, T M ^a   Nave J F ^b   Casara, P ^b,c   Tyms, A S ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b SANOFI   (France)

^c INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Acyclonucleotide analogue; Drug combination; Drug resistance; HIV 1; MDL 74968; Reverse transcriptase inhibitor

Indexed keywords

9 [2 METHYLIDENE 3 (PHOSPHONOMETHOXY)PROPYL]GUANINE; ADEFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ARGININE; DIDANOSINE; GUANINE DERIVATIVE; LAMIVUDINE; LYSINE; NEVIRAPINE; NEW DRUG; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG RESISTANCE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS GENE; VIRUS MUTANT; VIRUS REPLICATION;

EID: 0029737883     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029600700505     Document Type: Article

References (32)

1. Balzarini, J., Hao, Z., Herdewijn, P., Johns, D.G., and De Clercq, E. (1991) Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci USA 88: 1499-1503.
2. -1 evaluation of 9-(-2-(bispivaloyloxy-methyl)phosphonylmethoxy) adenine (bis-POM PMEA) an orally bioavailable prodrug of the anti-HIV nucleotide, PMEA. Antiviral Res 26: A229.
3. Brennan, T.M., Taylor, D.L., Bridges, C.G., Leyda, J.P., and Tyms, A.S. (1995) The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Antiviral Res 26: 173-187.
4. Bridges, C.G., Taylor, D.L., Ahmed, S.P., Brennan, T.M., Tyms, A.S., Homsperger, J.-M., Nave, J.-F., and Casara, P. (1995) MDL, 74, 968, a new acyclonucleotide analogue: Activity against HIV in vitro and in the hu-PBL-SCID/beige mouse model of infection. Antimicrob Agents Chemother 40: 1072-1077.
5. Casara, P., Altenburger, J.-M., Taylor, D.L., Tyms, A.S., Kenny, M., and Nave, J.-F. (1995) Synthesis and antiviral activity of rigid acyclonucleotide analogs. Bioorg Med Chem Lett 5: 1275-1280.
6. Choo, V. (1995) Combination superior to zidovudine in Delta trial. Lancet 346: 895.
7. Chou, T.-C., and Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
8. D'Aquila, R.T., Johnson, V.A., Welles, S.L., Japour, A.J., Kuritzkes, D.R., De Gruttole, V., Reichelderfer, P.S., Coombs, R.W., Crumpacker, C.S., Kahn, J.O., and Richman, D.D. (1995) Zidovudine resistance and HIV-1 disease progression during antiviral therapy. Ann Intern Med 122: 401-408.
9. De Clercq, E., Sakuma, T., Baba, M., Pauwels, R., Balzarini, J., Rosenberg, I., and Holy, A. (1987) Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines. Antiviral Res 8: 261-272.
10. De Clercq, E. (1991) Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and - pyrimidines. Biochem Pharmacol 42: 963-972.
11. Egberink, H., Borst, M., Niphuis, H., Balzarini, J., Neu, H., Schellekens, H., De Clercq, E., Horzinek, M., and Koolen, M. (1990) Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. Proc Natl Acad Sci USA 87: 3087-3091.
12. Gangemi, J.D., Cozens, R.M., De Clercq, E , Balzarini, J., and Hochkeppel, H.K. (1989) 9-(2-phosphonomethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections. Antimicrob Agents Chemother 33: 1864-1868.
13. Gong, Y.F., Marshall, D.R., Srinivas, R.V., and Fridland, A. (1994) Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates. Antimicrob Agents Chemother 38: 1683-1687.
14. Gu, Z., Gao, Q., Fang, H., Salomon, H., Parniak, M.A., Goldberg, E., Cameron, J., and Wainberg, M.A. (1994) Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 38: 275-281.
15. Gu, Z., Salomon, H., Cherrington, J.M., Mulato, A.S., Chen, M.S., Yarchoan, R., Foli, A., Sogocio, K.M., and Wainberg, M.A. (1995) K65R mutation of the human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl) adenine. Antimicrob Agents Chemother 39: 1888-1891.
16. Holy, A., and Rosenberg, I. (1987) Synthesis of 9-(2-phosphonylmethoxyethyl) adenine and related compounds. Collect Czech Chem Commun 52: 2801-2809.
17. Japour, A.J., Welles, S., D'Aquila, R.T., Johnson, V.A., Richman, D.D., Coombs, R.W., Reichelderfer, P.S., Kahn, J.O., Crumpacker, C.S., and Kuritzkes, D.R. (1995) Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. J Infect Dis 171: 1172-1179.
18. Kellam, P., Boucher, C.A., and Larder, B.A. (1992) Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 89: 1934-38.
19. Larder, B.A., and Kemp, S.D. (1989) Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
20. Larder, B.A., Darby, G., and Richman, D.D. (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243: 1731-1734.
21. Larder, B.A., Coates, K.E., and Kemp, S.D. (1991) Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J Virol 65: 5232-5236.
22. Larder, B.A., Kemp, S.D., and Harrigan, P.R. (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696-699.
23. Mellors, J.W., Larder, B.A., and Schinazi, R.F. (1995) Mutations in HIV-1 reverse transcriptase and proteinase associated with drug resistance, internat Antiviral News 3: 8-13.
24. Pauwets, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J., and De Clercq, E. (1988a) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 20: 309-321.
25. Pauwels, R., Balzarini, J., Schols, D., Baba, M., Desmyter, J., Rosenberg, I., Holy, A., and De Clercq, E. (1988b) Phosphonomethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother 32: 1025-1030.
26. Prichard, M.N., and Shipman, C. (1990) A three-dimensional model to analyze drug-drug interactions. Antiviral Res 14: 181-206.
27. Richman, D.D. (1993) Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 37: 1207-1213.
28. Richman, D.D., Havlir, D., Corbeil, J., Looney, D., Ignacio, C., Spector, S.A., Sullivan, J., Cheeseman, S., Barringer, K., Pauletti, D., Shih, C.-K., Myers, M., and Griffin, J. (1994) Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 68: 1660-1666.
29. Suhnel, J. (1990) Evaluation of synergism or antagonism for the combined action of antiviral agents. Antiviral Res 13: 23-40.
30. Tsai, C.-C., Follis, K.E., Sabo, A., Grant, R.F., Bartz, C., Nolte, R.E., Benveniste, R.E., and Bischofberger, N. (1994) Preexposure prophylaxis with 9-(2-phosphonomethoxyethyl)adenine against simian immunodeficiency virus infection in macaques. J Infect Dis 169: 260-266.
31. Tsai, C.-C., Follis, K.E., Sabo, A., Grant, R., and Bischofberger, N. (1995) Efficacy of 9-(2-phosphonomethoxyethyl)adenine treatment against chronic simian immunodeficiency virus infection in macaques. J Infect Dis 171: 1338-1343.
32. Zhang, D., Caliendo, A.M., Eron, J.J., Devore, K.M., Kaplan, J.C., Hirsch, M.S., and D'Aquila, R.T. (1994) Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the HIV-1 reverse transcriptase. Antimicrob Agents Chemother 38: 282-287.